Use the hyperlinks, where available to access additional clinical trial information.
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Atezolizumab Given in Combination With Cabozantinib Versus Docetaxel Monotherapy in Patients With Metastatic Non-Small Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy
Eligible patients will be randomised into one of two treating arms of the trial. In the first arm, patients will receive 1200mg of intravenous atezolizumab on Day 1 of each 21-day cycle and oral cabozantinib once daily on Days 1-21 of each cycle. In the second arm, patients will receive 75mg/m2 of intravenous docetaxel on Day 1 of each 21-day cycle.